The FDA has historically favored abstinence as being the endpoint in trials to develop remedies for substance use disorders. Abstinence has been evaluated applying absence of constructive urine drug assessments, absence of self-described drug use, and on a regular basis attending sessions where by drug use is assessed.WHO announces growth of curren